Remimazolam Versus Propofol During Hysteroscopy: A Systematic Review And Meta-Analysis of Nine Randomized Controlled Trials
Clinical Therapeutics
Research outputs
مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.
3,288 مُخرَج
Clinical Therapeutics
Journal of Emergency Medicine
Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.
Patient Preference and Adherence · مجلد Volume 20 · 1-21
Background: Medication adherence is critical for achieving optimal glycemic control and preventing diabetes-related complications. However, poor adherence remains a major barrier to effective diabetes management worldwide. Evidence regarding factors associated with medication adherence among adults with diabetes in Saudi Arabia remains limited. This study aimed to assess medication adherence among adults with diabetes and examine associations of sociodemographic, clinical, pharmacist-related, and digital health factors with adherence levels. Methods: A cross-sectional study was conducted among adults with type 1 or type 2 diabetes attending a specialized diabetes center in Jazan, Saudi Arabia, during February-March 2025. Participants were recruited using non-probability convenience sampling. Of 489 patients approached, 388 completed the questionnaire, yielding a response rate of 79.3%. Data were collected using a bilingual (Arabic/English) electronic questionnaire. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Descriptive statistics, bivariate analyses, correlation analysis, and multinomial logistic regression were performed using IBM SPSS Statistics version 27. Results: Overall, 77.1% of participants demonstrated low medication adherence, while 16.5% and 6.4% demonstrated moderate and high adherence, respectively. In the adjusted multinomial logistic regression model, higher satisfaction with the current diabetes management plan was significantly associated with greater odds of moderate adherence (OR=1.650, 95% CI: 1.212-2.245, P=0.001) and high adherence (OR=2.038, 95% CI: 1.165-3.565, P=0.013) compared with low adherence. Insulin use was associated with moderate vs low adherence (OR=2.175, 95% CI: 1.008-4.692, P=0.048), but not with high adherence. Participants who did not use mobile applications or digital health tools had higher odds of high vs low adherence than those who used such tools (OR=2.685, 95% CI: 1.007-7.154, P=0.048). Age and comorbid conditions were not significantly associated with adherence level in the adjusted model. Frequency of pharmacist consultation was significant overall (P=0.001), although individual category comparisons did not demonstrate a consistent pattern across adherence levels. Multicollinearity diagnostics indicated no problematic collinearity (VIF=1.04-1.34; tolerance ≥0.75). Conclusion: Medication adherence was predominantly low among study participants. Higher satisfaction with diabetes management was consistently associated with greater adherence, while insulin use and digital health tool use showed category-specific associations. The unexpected association between digital-tool non-use and high adherence should be interpreted cautiously and does not establish a causal effect of digital technology on adherence. Further longitudinal and prospective studies are warranted to clarify these associations and determine how structured pharmacist engagement and personalized digital-health strategies can be optimally incorporated into patient-centered diabetes care.
Food Science & Nutrition · مجلد 14 (10) · e72441-e72441
ABSTRACT Argania spinosa L. is endemic to a small region in southwestern Morocco and has been used for food and medicinal purposes for decades. This study evaluates the hepatoprotective and potential cardioprotective effects of roasted Argan seed oil (HGAT) and non‐roasted Argan seed oil (HGANT) in a streptozotocin‐induced experimental diabetic model. An experimental approach in diabetic rats treated with HGAT or HGANT was used to assess oxidative stress, liver enzymes, and lipid metabolism. Diabetic rats were administered 2 mL/kg body weight/day of HGAT or HGANT. Biochemical analyses measured blood glucose levels, liver enzyme activity (ALT, AST, LDH), oxidative stress markers (MDA, GSH, CAT), lipid profiles, and hepatic glycogen content. Histopathological examinations assessed collagen deposition and fibrosis in liver and heart tissues. Both HGAT and HGANT significantly reduce oxidative stress and improve lipid profiles in diabetic rats. Notably, 2 mL/kg body weight/day of HGAT treatments decreased blood sugar levels to values comparable to those observed with metformin ( p > 0.05). Histopathological analysis revealed that both oils improved hepatic architecture, reduced lipid droplet accumulation, and decreased collagen deposition in the liver. In cardiac tissue, HGAT and HGANT improved myocardial structure and significantly reduced collagen deposition, indicating attenuation of cardiac fibrosis. The roasting process did not affect total cholesterol, triglycerides, hepatic glycogen, or oxidative stress markers. Argan oil demonstrates promising hepatoprotective and lipid‐modulating effects in diabetic conditions, with additional cardioprotective potential, supporting its ethnomedicinal use in metabolic disorders. Further studies are warranted to clarify its underlying mechanisms, long‐term effects, and potential interactions with standard antidiabetic therapies.
ChemistrySelect · مجلد 11 (38)
ABSTRACT Isatin‐based ligands have been recognized for their remarkable pharmacological potential and this study reports the synthesis, characterization, and biological evaluation of three novel nickel(II)‐isatin hydrazone complexes ( C1–C3 ). The complexes were characterized by FT‐IR, UV–vis, mass spectroscopy, DFT, magnetic, conductivity and thermal analyses indicating octahedral geometry and appreciable heat stability. Molecular electrostatic potential mapping gave information on their electronic properties. DFT calculations indicated decreased HOMO–LUMO gaps indicating increased reactivity. Biological screening showed remarkable anticancer activity against HCT‐116, A549, MCF‐7, and HepG‐2 cell lines (IC 50 = 7.22–17.33 µM), potent antibacterial and antifungal activities comparable to ciprofloxacin and clotrimazole against Staphylococcus aureus and Candida albicans , and significant antioxidant activity with 59%–69% of the radical scavenging. Molecular docking and dynamics studies showed the stable binding interactions with the target enzyme FabH especially for complex C3 . These results collectively highlight C1‐C3 as multifunctional therapeutic candidates with stability and reactivity properties, making them attractive scaffolds for pharmacological development.
Cell Biochemistry and Function · مجلد 44 (10) · e70321-e70321
Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.
Health Services Insights · مجلد 19
Background and objective Diabetes mellitus requires continuous self-management, medication adherence, and regular healthcare follow-up. Tele-pharmacy is an emerging care delivery model that may improve access, engagement, and chronic disease management, but evidence on diabetic patients’ experiences with tele-pharmacy in Saudi Arabia remains limited. This study aimed to assess perceptions and experiences of tele-pharmacy services among adults with diabetes in Saudi Arabia who use them and to describe diabetes self-management behaviours and perceived diabetes-related outcomes. Methods We conducted a cross-sectional survey of adults with diabetes in Saudi Arabia using a structured questionnaire distributed through convenience sampling; analyses were restricted to the 377 respondents who reported using tele-pharmacy services. Associations between categorical variables were assessed using the Chi-square test or Fisher’s exact test, as appropriate. We examined associations between participant demographic characteristics, including gender, age group, educational level, diabetes type, and diabetes duration, and perceived tele-pharmacy outcomes. Results Among the 377 tele-pharmacy users, 84.6% found it easier to access than traditional services. Participants showed favorable self-management behaviors, particularly in adherence, glucose monitoring, and diet. Satisfaction was high across accessibility, convenience, and care quality. Most participants reported improved medication adherence, blood glucose levels, dietary habits, and reduced complications. No statistically significant associations were observed between perceived tele-pharmacy outcomes and gender, age group, or diabetes type. However, diabetes duration was significantly associated with perceived reductions in diabetes-related complications (p=0.010), while higher educational attainment was associated with better disease understanding (p=0.020), blood glucose monitoring (p=0.011), and physical activity (p=0.044). Conclusions In this cross-sectional survey, adults with diabetes in Saudi Arabia who used tele-pharmacy services reported generally favourable perceptions regarding accessibility and satisfaction. These findings describe favourable perceptions among self-selected tele-pharmacy users, cannot be generalized to all adults with diabetes, and should not be interpreted as evidence of a causal effect of tele-pharmacy on clinical outcomes.
Journal of the National Medical Association · 101123-101123
Journal of Pubnursing Sciences · مجلد 4 (03) · 113-122
Background: Schizophrenia severely impacts quality of life (QoL), and medication adherence is crucial for managing symptoms and preventing relapse. However, adherence remains a significant challenge in resource-limited settings. Aims: This study aimed to evaluate the relationship between medication adherence and quality of life among adult patients with schizophrenia in North-Western Nigeria. Methods: A descriptive cross-sectional study was conducted involving 865 patients across seven states in North-Western Nigeria. Participants were selected using a multistage sampling technique. Adherence and QoL were assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8) and the WHOQOL-BREF, respectively. Data analysis included descriptive statistics, chi-square tests, and binary logistic regression (p < 0.05). Results: Findings revealed that 44.9% of participants had good adherence, 32.8% had moderate adherence, and 22.3% were poorly or non-adherent. Significant predictors of non-adherence included high medication costs (AOR = 4.25), adverse side effects (AOR = 3.14), poor drug accessibility (AOR = 2.94), polypharmacy (AOR = 2.71), and low educational attainment (AOR = 2.08). Good medication adherence was significantly associated with improved QoL across the physical, psychological, social, and environmental domains (p < 0.001). Conclusion: Medication adherence among these patients is suboptimal, primarily due to socio-economic and clinical barriers. Since adherence strongly predicts improved QoL, interventions should focus on affordable medication access, side-effect management, and psychoeducation.
Cardiology in Review
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).
Cureus · مجلد 18 (9) · e116820-e116820
Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.
Journal of Cardiovascular Development and Disease · مجلد 13 (10) · 478-478
Background: Tricuspid regurgitation (TR) increases mortality but remains undertreated due to high surgical risks. Transcatheter tricuspid valve interventions (TTVI) offer safer alternatives, improving functional status and quality of life. However, many candidates for TTVI have trans-tricuspid CIED leads that may interfere with procedural imaging and device deployment and may be exposed to dislodgement, entrapment, or jailing. Evidence regarding both clinical outcomes and postprocedural CIED function in this population remains limited. Existing trial evidence for this population is scarce, requiring further safety analysis. To our knowledge, this is the first meta-analysis to address the comparative risk of complications and residual TR in patients with vs. without CIEDs. Methods: We searched for relevant articles up to March 2026 from PubMed, Scopus, Cochrane Library, and Web of Science. Two independent reviewers extracted data from the selected studies, including baseline information, outcomes, comorbidities, hospitalization metrics, TR severity, and complications. All data analyses were performed using R version 4.4.1. Results: Ten studies comprising 5415 patients were included. Nine comparative studies contributed to the quantitative synthesis, whereas one single-arm study contributed only to the narrative synthesis of CIED-specific mechanical and electrical outcomes. In patients undergoing TTVI, across two studies, patients with CIEDs had a nominally lower risk of single-leaflet device attachment (RR 0.34, 95% CI 0.12–0.94; nominal p = 0.037); however, this exploratory finding should be considered hypothesis-generating. However, no statistically significant differences were observed between groups for cardiovascular death (RR 1.30, p = 0.815), device embolization (RR 1.62, p = 0.666), device malposition (RR 1.10, p = 0.909), stroke (RR 0.52, p = 0.335), hospitalization for heart failure (RR 1.02, p = 0.931), in-hospital mortality (RR 1.02, p = 0.959), major adverse events (RR 0.74, p = 0.635), major bleeding (RR 0.70, p = 0.187), or residual tricuspid regurgitation of mild (RR 0.98, p = 0.686) or moderate severity (RR 1.01, p = 0.646). CIED-specific outcomes were reported heterogeneously. Lead function was generally preserved after T-TEER in carefully selected patients, whereas studies of TTVR with jailed leads reported lead failure or malfunction ranging from 5.8% to 21% in individual cohorts. Conclusions: Among the comparative outcomes available for quantitative pooling, no statistically significant differences were detected between patients with and without CIEDs for most procedural and postprocedural outcomes. However, CIED-specific risks differed according to the intervention. Lead function was generally preserved after T-TEER in carefully selected patients, whereas lead jailing during TTVR was associated with clinically relevant lead malfunction in some cohorts. Therefore, the absence of significant differences in pooled clinical outcomes should not be interpreted as evidence that TTVI does not affect CIED function.
Journal of Clinical Medicine · مجلد 15 (19) · 7406-7406
Background/Objectives: Vernakalant is an atrial-selective antiarrhythmic used for rapid pharmacological cardioversion of recent-onset atrial fibrillation. This systematic review and meta-analysis evaluated the efficacy and safety of vernakalant compared with placebo, active antiarrhythmic therapy, and electrical cardioversion. Methods: PubMed, Embase, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to August 2026. Randomized clinical trials, clinical trials, and comparative observational studies evaluating vernakalant in adults with atrial fibrillation or atrial flutter were included. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using the Mantel–Haenszel random-effects model in RevMan 5.4. Results: Twenty controlled studies involving 4523 patients were included, of whom 2349 received vernakalant and 2174 received control therapy. Vernakalant significantly increased successful conversion to sinus rhythm compared with all controls (1234/2244 (55%) vs. 991/2147 (46.2%); RR = 1.63; 95% CI [1.34, 1.99]; p < 0.00001). The effect was strongest versus placebo (RR = 5.33; 95% CI [1.95, 14.60]; p = 0.001) and remained significant versus procainamide (111/178 (62.3%) vs. 83/172 (48.2%); RR = 1.29; 95% CI [1.07, 1.57]; p = 0.009) and flecainide (209/280 vs. 209/330 (63.3%); RR = 1.18; 95% CI [1.05, 1.33]; p = 0.007), but non-significant against amiodarone, propafenone, ibutilide, or electrical cardioversion. Safety outcomes did not differ significantly between groups, including all-cause mortality (RR = 1.23), drug discontinuation (RR = 0.98), serious adverse events (RR = 0.87), ventricular tachycardia (RR = 0.68), bradycardia (RR = 1.31), and hypotension (RR = 0.80). Conclusions: Vernakalant was associated with higher rates of conversion to sinus rhythm, while no statistically significant differences were observed in major safety outcomes. These findings support its use as a pharmacological option for rapid rhythm restoration in appropriately selected patients.
Medical Principles and Practice · 1-1
OBJECTIVE: Aims of the study were to evaluate the diagnostic performance of abdominal ultrasonography, specifically its positive predictive value, in children younger than 36 months presenting with suspected intussusception to the emergency department of a major tertiary care center in Saudi Arabia and to describe the associated clinical and sonographic features. METHODS: This retrospective study reviewed the medical records and radiological findings of 150 pediatric patients aged less than 36 months who presented with suspected intussusception to the emergency department in a major tertiary care center in Saudi Arabia between 2005 and 2015. Ultrasound was used as the initial diagnostic modality, and findings were confirmed using contrast enema, computed tomography scan, or intraoperative findings when applicable. RESULTS: Out of 150 suspected cases, 36 patients (24.0%) were confirmed to have intussusception. All 36 ultrasound-positive cases were subsequently confirmed by contrast enema, computed tomography, or surgery, giving a positive predictive value of 100% (36/36). Because the 114 ultrasound-negative patients were classified on the basis of clinical course rather than an independent reference standard, sensitivity, specificity, and negative predictive value could not be validly estimated and are not reported. Vomiting and bloody stool were significantly associated with confirmed diagnosis; no significant association was found with gender. CONCLUSION: In this single-center retrospective cohort, a positive abdominal ultrasound reliably predicted confirmed intussusception, supporting its established role as the first-line imaging modality for suspected pediatric intussusception. Although these regional data add local confirmation but given the retrospective design and the absence of an independent reference standard for ultrasound-negative cases, they should be interpreted with caution.
Cureus · مجلد 18 (9) · e116495-e116495
Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.